Pharmabiz
 

Cadila Healthacre net falls by 8% in FY'12, dividend at 150%

Our Bureau, MumbaiThursday, May 10, 2012, 15:35 Hrs  [IST]

Cadila Healthcare has posted disappointed performance during the year ended March 2011 due to significant rise in interest burden. Its consolidated net profit declined by 8.2 per cent to Rs.653 crore from Rs.711 crore in the previous year. Its EBDITA, however, improved by 9.4 per cent to Rs.1,137 crore from Rs.1,039 crore on account of higher other income. Its earnings per share declined to Rs.31.87 from Rs.34.73 in the last year. The scrip experienced volatile movements on BSE after the announcement of financial performance. It went to intra-day high level at Rs.750 and touched to lowest at Rs.714.20 as against previous day's close of Rs.734.20. It closed above Rs.745 today.

The board of directors has declared equity dividend of 175 per cent for the year ended March 2012. The interest cost went up by 164 per cent to Rs.184.90 crore from Rs.69.92 crore and its employees cost increased by 18.2 per cent to Rs.751.22 crore from Rs.635.55 crore.

The standalone net sales improved by 10.9 per cent to Rs.2413 crore from Rs.2,176 crore and its standalone net profit increased by 7.7 per cent to Rs.657.52 crore from Rs.610.28 crore in the previous year.

The company's domestic formulation business posted sales growth of 38 per cent to Rs.499 crore during the last quarter of FY'12. It launched 40 new products which included 16 line extensions. Of these, 10 were first in India launches. Its formulation exports to US during the fourth quarter increased by 26 per cent. The group entered into an agreement with Microbix Biosystems Inc., a biotechnology company commercializing novel technologies to market the thromobolytic drug, Urokinase in the North American market. The group filed 7 ANDAs during the quarter taking the cumulative to 148 ANDA flings. The group also filed 4 DMFs, taking the cumulative number to 107 DMFs. It filed 7 additional dossiers for new products in the European markets, taking cumulative number of new product dossier filings to 136. In Japan, I filed 4 new products and received 3 approvals during the fourth quarter.

 
[Close]